Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study

Albanese M, Marrone G, Paolino A, Di Lauro M, Di Daniele F, Chiaramonte C, D'Agostini C, Romani A, Cavaliere A, Guerriero C, Magrini A, Mercuri NB, Di Daniele N, Noce A. Pharmaceuticals, 2022; 15(2):253.

Controlled trialHumans

Design

Controlled trial

Subjects

90 patients with COVID-19 and no or mild symptoms: 45 treated and 45 controls

Dose used in the study

1,800 mg a day of ultramicronised palmitoylethanolamide, as microgranules taken under the tongue (Normast MPS)

Duration

28 days

What was measured

Blood markers of inflammation, oxidative stress and clotting, lymphocyte counts and antibody levels

What the authors reported

The authors reported lower CRP, IL-6 and neutrophil-to-lymphocyte ratio in the treated group at 28 days, lower D-dimer and higher antibody levels. Adverse events were not visible on the page checked.

Limits of this study

The paper calls the design a randomised case-control study. There was no placebo group, which the authors name as a limit. All outcomes were blood markers, and the study did not report clinical outcomes such as symptoms or recovery time. Patients had no or mild symptoms. The study received no external funding.

Source

doi:10.3390/ph15020253

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.